I reckon that’s a fair post. Question has to be raised about the claim that they will be cash neutral in 2021 based on this deal alone. if these numbers stack up it’s a game changing deal. If the prescriptions are growing in other deals as previously announced then it is clear they are on path to profit. problem is....the ifs. Once the revenue is in the bank the market will respond. However still a lot of South Korean in the memory banks of investors. I do hope it is legit for long term holders
MXC Price at posting:
2.8¢ Sentiment: Hold Disclosure: Held
